Spondylitis, AnkylosingPhase 2AS SpA axSpANCT04947579
A Study of CC-99677 in Participants With Active Ankylosing Spondylitis
A Phase 2 study testing CC-99677 in people with Spondylitis, Ankylosing, run by Celgene at 63 sites in 8 countries.
Trial summary
This study is designed to learn about response to CC-99677 treatment by measuring signs and symptoms of Ankylosing Spondylitis (AS), objective measures of disease activity, quality of life assessments, pharmacokinetics, safety, and tolerability over a 12-week double-blind period. Read more about this study
- Who is it for?
- Ages 18 to 65 years
- Conditions the study is for
- Spondylitis, Ankylosing
- What is being tested?
- CC-99677
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 167 participants
- Where
- 63 sitesin 8 countries
- Study dates
- 25 Aug 2021to 21 Feb 2023
- Phase
- Phase 2
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Diagnosis of Ankylosing Spondylitis (AS) fulfilling the modified New York criteria
- Active axial disease at Screening and Baseline defined by a Bath Ankylosing
- Spondylitis Disease Activity Index (BASDAI) score ≥ 4 and Total Back Pain ≥ 4
- Failed prior treatment with at least 2 NSAIDs for at least 4 weeks each
- Participant has never received a biologic therapy eg, tumor necrosis factor (TNF) antagonist or monoclonal antibody [mAb] against IL-17A (biologic naive main study), or have taken more than one biologic therapy (biologic-failure substudy) for the treatment of AS
Who cannot join
- Radiographic evidence of total ankylosis of the spine
- Clinically significant back pain caused by diseases other than AS
- Concurrent treatment or treatment within the 6 months prior to Baseline with cell depleting biologic agents
- Participation in any study of an investigational drug, including those for COVID-19
- History of malignancy
- Oral corticosteroids (prednisone or equivalent) > 10 mg/day systemically for ≥ 2 weeks prior to Baseline Visit
Trial locations and contacts
63 sites in 8 countries.
63 sites in 8 countries
United States16 sites
Local Institution - 029
Austin, Texas, 78731
Local Institution - 028
Cleveland, Ohio, 44106
Local Institution - 006
Colleyville, Texas, 76034
Local Institution - 004
Dayton, Ohio, 45417
Local Institution - 003
Duncansville, Pennsylvania, 16635
Local Institution - 024
Flagstaff, Arizona, 86001
Local Institution - 019
Fort Worth, Texas, 76107
Local Institution - 021
Gilbert, Arizona, 58297
Local Institution - 008
Houston, Texas, 77099
Local Institution - 005
Jackson, Tennessee, 38305
Local Institution - 002
Memphis, Tennessee, 38119
Local Institution - 022
Phoenix, Arizona, 95037
Local Institution - 009
Portland, Oregon, 97239
Local Institution - 026
Saint Clair Shores, Michigan, 48081
Local Institution - 025
Tucson, Arizona, 85704
Local Institution - 017
Tustin, California, 92780
Poland14 sites
Local Institution - 311
Bialystok, 15-077
Local Institution - 315
Bialystok, 15-351
Local Institution - 305
Bydgoszcz, 85-065
Local Institution - 302
Bydgoszcz, 85-168
Local Institution - 301
Elblag, 82-300
Local Institution - 307
Katowice, 40-282
Local Institution - 300
Krakow, 30-002
Local Institution - 308
Krakow, 30-363
Local Institution - 310
Nowa Sól, 67-100
Local Institution - 313
Onyksowa 10, 20-582
Local Institution - 312
Sochaczew, 96-500
Local Institution - 306
Torun, 87-100
Local Institution - 303
Warsaw, 02-691
Local Institution - 309
Wroclaw, 52-416
Czechia8 sites
Local Institution - 205
Brno, 61141
Local Institution - 206
Ostrava, 702 00
Local Institution - 207
Ostrava, 702 00
Local Institution - 201
Pardubice, 530 02
Local Institution - 202
Prague, 13000
Local Institution - 203
Prague, 140 00
Local Institution - 211
Prague, 148 00
Local Institution - 204
Uherské Hradište, 686 01
Turkey (Türkiye)8 sites
Local Institution - 702
Adapazarı, 54100
Local Institution - 707
Altındağ/Ankara, 06230
Local Institution - 700
Ankara, 06100
Local Institution - 701
Edirne, 22030
Local Institution - 705
Istanbul, 34098
Local Institution - 706
Izmir, 35100
Local Institution - 704
Karabağlar, 35360
Local Institution - 703
Trabzon, 61080
Spain7 sites
Local Institution - 604
A Coruña, 15006
Local Institution - 607
Barcelona, 08035
Local Institution - 606
Córdoba, 14001
Local Institution - 605
Mérida, 06800
Local Institution - 601
Sabadell, 8208
Local Institution - 602
Santiago de Compostela, 15706
Local Institution - 603
Seville, 41013
China5 sites
Local Institution - 151
Guangzhou, 510630
Local Institution - 152
Hangzhou, 310014
Local Institution - 153
Huangpu District, 200000
Local Institution - 154
Shanghai, Shanghai Municipality, 200040
Local Institution - 150
Wuhan, 430030
Romania4 sites
Local Institution - 400
Brasov, 500283
Local Institution - 404
Bucharest, 011025
Local Institution - 402
Bucharest, 011172
Local Institution - 403
Bucharest, 011172
About this study
Official title: A Phase 2 Multicenter, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of CC-99677 in Subjects With Active Ankylosing Spondylitis
This study is designed to learn about response to CC-99677 treatment by measuring signs and symptoms of Ankylosing Spondylitis (AS), objective measures of disease activity, quality of life assessments, pharmacokinetics, safety, and tolerability over a 12-week double-blind period.
- Conditions
- Spondylitis, Ankylosing
- Being tested
- CC-99677, Placebo
- Keywords
- Ankylosing Spondylitis, CC-99677, MK2inhibitor, Spinal Diseases, Bone Diseases, Musculoskeletal Diseases, Arthritis, Joint Diseases
- Medical subject headings
- Spondylitis, Ankylosing, Spinal Diseases, Bone Diseases, Musculoskeletal Diseases, Arthritis, Joint Diseases
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
CC-99677Drug
Oral
PlaceboOther
Oral
| Study group | Role | What they receive |
|---|---|---|
| Administration of CC-99677 150 mg QD PO | Experimental | 49 participants will be randomized to CC-99677 150 mg in biologic naive main study Receives: Drug: CC-99677 |
| Administration of CC-99677 60mg QD PO | Experimental | 49 participants will be randomized to CC-99677 60 mg in biologic naive main study Receives: Drug: CC-99677 |
| Administration of Placebo QD PO | Placebo comparator | 49 participants will be randomized to placebo in biologic naive main study Receives: Other: Placebo |
| Administration of CC-99677 150 mg QD PO. | Experimental | 20 participants will be randomized to CC-99677 150 mg in biologic-failure substudy Receives: Drug: CC-99677 |
| Administration of CC-99677 60mg QD PO. | Experimental | 20 participants will be randomized to CC-99677 60 mg in biologic-failure substudy Receives: Drug: CC-99677 |
| Placebo additional dose cohort | Placebo comparator | 10 participants will be randomized to placebo in biologic-failure substudy Receives: Other: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Percentage of Participants Who Achieve ASAS 20 at Week 12
Percentage of participants who achieve an improvement in disease activity from baseline of ≥ 20% and ≥ 1 unit in at least 3 of the 4 SpondyloArthritis International Society (ASAS) domains on a scale of 0 to 10, and no worsening from baseline of ≥ 20% and ≥ 1 unit in the remaining domain on a scale of 0 to 10. Baseline is the last non-missing value on or before the date of the first dose of investigational product. The four ASAS Domains are:
- Patient Global Assessment of Disease (0 to 10 unit Numerical Rating Scale [NRS]);
- Total Back Pain NRS;
- Function (the Bath Ankylosing Spondylitis Functional Index [BASFI] score NRS);
- Inflammation (mean of Bath Ankylosing Spondylitis Disease Activity Index [BASDAI] NRS Questions #5 and #6 for morning stiffness).
Measured: Week 12
Secondary outcomes (7)
Percentage of Participants Who Achieve ASAS 40 at Week 12
Percentage of participants who achieve an improvement in disease activity from baseline of ≥ 40% and ≥ 2 unit in at least 3 of the 4 SpondyloArthritis International Society (ASAS) domains on a scale of 0 to 10, and no worsening at all from baseline in the remaining domain. Baseline is the last non-missing value on or before the date of the first dose of investigational product. The four ASAS Domains are:
- Patient Global Assessment of Disease (0 to 10 unit Numerical Rating Scale [NRS]);
- Total Back Pain NRS;
- Function (the Bath Ankylosing Spondylitis Functional Index [BASFI] score NRS);
- Inflammation (mean of Bath Ankylosing Spondylitis Disease Activity Index [BASDAI] NRS Questions #5 and #6 for morning stiffness).
Measured: Week 12
Change From Baseline in Ankylosing Spondylitis Disease Activity Score With CRP (ASDAS-CRP) at Week 12
ASDAS-CRP is a score of disease activity that combines patient reported assessments of back pain (Bath Ankylosing Spondylitis Disease Activity Index [BASDAI] question 2), duration of morning stiffness (BASDAI question 6), peripheral joint pain and/or swelling (BASDAI question 3), general wellbeing, and CRP in a weighted manner. The cut-off values for disease activity states and improvement scores are defined as follows: <1.3 inactive disease, ≥1.3 and <2.1 low disease activity, ≥2.1 and ≤3.5 high disease activity and 3.5 very high disease activity. The minimum clinically important difference (MCID) are defined as: change of at least 1.1 unit for 'clinically important improvement' and change of at least 2.0 units for 'major improvement'. Baseline is the last non-missing value on or before the date of the first dose of investigational product. ASDAS-CRP Formula: 0.12xBack Pain+0.06xDuration of Morning Stiffness+0.11xPatient Global+0.07xPeripheral Pain/Swelling+0.58xln(CRP+1)
Measured: Baseline and Week 12
Change From Baseline in BASDAI at Week 12
Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) is a composite score based on a self-administered survey of six questions using a 0 to 10 unit numerical rating scale (NRS) that assesses five major symptoms of AS during the last week: 1) fatigue; 2) spinal pain; 3) peripheral joint pain/swelling; 4) areas of localized tenderness; 5a) morning stiffness severity upon wakening; 5b) morning stiffness duration upon wakening. To give each of the five symptoms equal weighting, the mean of the two scores relating to morning stiffness is taken. The resulting 0 to 50 score is divided by 5 to give a final 0 to 10 BASDAI score. A BASDAI score of 4 or greater is considered to be indicative of active AS disease. Baseline is the last non-missing value on or before the date of the first dose of investigational product.
Measured: Baseline and Week 12
Change From Baseline in BASFI at Week 12
Bath Ankylosing Spondylitis Functional Index (BASFI) is a composite score based on a self administered survey of ten questions using a 0 to 10 unit numerical rating scale (NRS) that assesses degree of mobility and functional ability during the last week. The questionnaire consists of eight questions regarding function in AS and the two last questions reflecting ability to cope with everyday life. The left-hand box of 0 represents "easy," and the right-hand box represents "impossible." The resulting 0 to 100 score is divided by 10 to give a final 0 to 10 BASFI score. A higher BASFI score correlates to reduced functional ability. Baseline is the last non-missing value on or before the date of the first dose of investigational product.
Measured: Baseline and Week 12
Change From Baseline in the SPARCC SI Joint Score at Week 12
Change from Baseline in the Spondyloarthritis Research Consortium of Canada (SPARCC) scores of the sacroiliac joints. The SPARCC assesses 16 sites for enthesitis using a score of "0" for no activity or "1" for activity. Sites assessed include Medial epicondyle (left/right [L/R]), Lateral epicondyle (L/R), Supraspinatus insertion into greater tuberosity of humerus (L/R), Greater trochanter (L/R), Quadriceps insertion into superior border of patella (L/R), Patellar ligament insertion into inferior pole of patella or tibial tubercle (L/R), Achilles tendon insertion into calcaneum (L/R), and Plantar fascia insertion into calcaneum (L/R). The SPARCC is the sum of all site scores (range 0 to 16). Higher scores indicate more severe enthesitis. Baseline is the last non-missing value on or before the date of the first dose of investigational product.
Measured: Baseline and Week 12
Change From Baseline in the SPARCC Spine Score at Week 12
Change from Baseline in the Spondyloarthritis Research Consortium of Canada (SPARCC) scores of the total spine. All 23 disco-vertebral units (DVU) of the spine (from C2 to S1) were scored for bone marrow edema. A single DVU has 18 scoring units, and each has score of 0 or 1, bringing the maximum total score to 414, the sum ranges from 0 to 414 with higher scores reflecting worse disease.
Baseline is the last non-missing value on or before the date of the first dose of investigational product.
Measured: Baseline and Week 12
Percent Change From Baseline in hsCRP at Week 12
Percent change from baseline in high-sensitivity C-reactive protein (hsCRP). Baseline is the last non-missing value on or before the date of the first dose of investigational product.
Measured: Baseline and Week 12
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted1 Jul 2021
- Study start25 Aug 2021
- Primary completion21 Feb 2023
- Study completion21 Feb 2023
Why it stopped: The study has been terminated due to Non-Safety reasons because of lack of efficacy in the short-term acute phase.
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Spondylitis, AnkylosingStudies of the same condition, open and under way.
- More trials run by CelgeneThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 167 participants (actual)
Sponsor and investigators
- Lead sponsor
- Celgene
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Bristol-Myers Squibb, MD, Study director, Bristol-Myers Squibb
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04947579
- Sponsor's protocol ID
- CC-99677-AS-001
- Other IDs
- U1111-1265-3951, 2019-004108-37, 2019
- Acronym
- AS SpA axSpA
- Status last verified
- Apr 2024
- First submitted
- 23 Jun 2021
- Last updated
- 1 May 2024
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- Yes
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- Yes: Information relating to our policy on data sharing and the process for requesting data can be found at the following link: https://www.celgene.com/research-development/clinical-trials/clinical-trials-data-sharing/
Publications
Maksymowych WP, Yeshokumar A, Cerullo E, Lambert RGW, Sliwinska-Stanczyk P, Klimiuk P, Kepich R, Pachai C, Zhu M, Liu J, Landis J, Goti V, Greenberg S. Phase II randomised, placebo-controlled study to evaluate the efficacy and safety of an MK2 inhibitor in ankylosing spondylitis. RMD Open. 2026 May 21;12(2):e006527. doi: 10.1136/rmdopen-2025-006527.
PubMed 42167889
Study at a glance
From the registry record, last updated by the sponsor on 1 May 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Phase 2 Multicenter, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of CC-99677 in Subjects With Active Ankylosing Spondylitis
- ClinicalTrials.gov ID
- NCT04947579
- Acronym / sponsor ID
- AS SpA axSpA / CC-99677-AS-001
- Conditions
- Spondylitis, Ankylosing
- Keywords
- Ankylosing Spondylitis, CC-99677, MK2inhibitor, Spinal Diseases, Bone Diseases, Musculoskeletal Diseases, Arthritis, Joint Diseases
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- TerminatedReason stopped: The study has been terminated due to Non-Safety reasons because of lack of efficacy in the short-term acute phase.
- Enrolment
- 167 participants (actual)
- Lead sponsor
- CelgeneIndustry (pharma, biotech, devices)
- Study start
- 25 Aug 2021 (actual)
- Primary completion
- 21 Feb 2023 (actual)
- Study completion
- 21 Feb 2023 (actual)
- First posted
- 1 Jul 2021 (actual)
- Results
- Posted 1 May 2024
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study is designed to learn about response to CC-99677 treatment by measuring signs and symptoms of Ankylosing Spondylitis (AS), objective measures of disease activity, quality of life assessments, pharmacokinetics, safety, and tolerability over a 12-week double-blind period.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 6
| Arm | Type | Receives |
|---|---|---|
| Administration of CC-99677 150 mg QD PO | Experimental | Drug: CC-9967749 participants will be randomized to CC-99677 150 mg in biologic naive main study |
| Administration of CC-99677 60mg QD PO | Experimental | Drug: CC-9967749 participants will be randomized to CC-99677 60 mg in biologic naive main study |
| Administration of Placebo QD PO | Placebo comparator | Other: Placebo49 participants will be randomized to placebo in biologic naive main study |
| Administration of CC-99677 150 mg QD PO. | Experimental | Drug: CC-9967720 participants will be randomized to CC-99677 150 mg in biologic-failure substudy |
| Administration of CC-99677 60mg QD PO. | Experimental | Drug: CC-9967720 participants will be randomized to CC-99677 60 mg in biologic-failure substudy |
| Placebo additional dose cohort | Placebo comparator | Other: Placebo10 participants will be randomized to placebo in biologic-failure substudy |
Who may qualify
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- Diagnosis of Ankylosing Spondylitis (AS) fulfilling the modified New York criteria
- Active axial disease at Screening and Baseline defined by a Bath Ankylosing
- Spondylitis Disease Activity Index (BASDAI) score ≥ 4 and Total Back Pain ≥ 4
- Failed prior treatment with at least 2 NSAIDs for at least 4 weeks each
- Participant has never received a biologic therapy eg, tumor necrosis factor (TNF) antagonist or monoclonal antibody [mAb] against IL-17A (biologic naive main study), or have taken more than one biologic therapy (biologic-failure substudy) for the treatment of AS
Key exclusion criteria (6 listed)
- Radiographic evidence of total ankylosis of the spine
- Clinically significant back pain caused by diseases other than AS
- Concurrent treatment or treatment within the 6 months prior to Baseline with cell depleting biologic agents
- Participation in any study of an investigational drug, including those for COVID-19
- History of malignancy
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| CC-99677Oral | Drug | Administration of CC-99677 150 mg QD PO, Administration of CC-99677 150 mg QD PO., Administration of CC-99677 60mg QD PO, Administration of CC-99677 60mg QD PO. |
| PlaceboOral | Other | Administration of Placebo QD PO, Placebo additional dose cohort |
Primary outcome
Percentage of Participants Who Achieve ASAS 20 at Week 12
Time frame: Week 12
Percentage of participants who achieve an improvement in disease activity from baseline of ≥ 20% and ≥ 1 unit in at least 3 of the 4 SpondyloArthritis International Society (ASAS) domains on a scale of 0 to 10, and no worsening from baseline of ≥ 20% and ≥ 1 unit in the remaining domain on a scale of 0 to 10. Baseline is the last non-missing value on or before the date of the first dose of investigational product. The four ASAS Domains are: * Patient Global Assessment of Disease (0 to 10 unit Numerical Rating Scale [NRS]); * Total Back Pain NRS; * Function (the Bath Ankylosing Spondylitis Functional Index [BASFI] score NRS); * Inflammation (mean of Bath Ankylosing Spondylitis Disease Activity Index [BASDAI] NRS Questions #5 and #6 for morning stiffness).
7 secondary outcomes
Percentage of Participants Who Achieve ASAS 40 at Week 12
Time frame: Week 12
Change From Baseline in Ankylosing Spondylitis Disease Activity Score With CRP (ASDAS-CRP) at Week 12
Time frame: Baseline and Week 12
Change From Baseline in BASDAI at Week 12
Time frame: Baseline and Week 12
Change From Baseline in BASFI at Week 12
Time frame: Baseline and Week 12
Change From Baseline in the SPARCC SI Joint Score at Week 12
Time frame: Baseline and Week 12
Change From Baseline in the SPARCC Spine Score at Week 12
Time frame: Baseline and Week 12
Percent Change From Baseline in hsCRP at Week 12
Time frame: Baseline and Week 12
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 1 May 2024.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Derived from this study: PubMed 42167889Maksymowych WP, Yeshokumar A, Cerullo E, Lambert RGW, Sliwinska-Stanczyk P, Klimiuk P, Kepich R, Pachai C, Zhu M, Liu J, Landis J, Goti V, Greenberg S. Phase II randomised, placebo-controlled study to evaluate the efficacy and safety of an MK2 inhibitor in ankylosing spondylitis. RMD Open. 2026 May 21;12(2):e006527. doi: 10.1136/rmdopen-2025-006527.
- BMS Clinical Trial InformationLink provided by the sponsor.
- FDA Safety Alerts and RecallsLink provided by the sponsor.
- BMS Clinical Trial Patient RecruitingLink provided by the sponsor.
- Individual participant dataSharing planned: Yes. Information relating to our policy on data sharing and the process for requesting data can be found at the following link: https://www.celgene.com/research-development/clinical-trials/clinical-trials-data-sharing/
Related trials for Spondylitis, Ankylosing
RecruitingPhase 1
A Study of HB0017 Injection in Healthy Volunteers to Evaluate Safety and Tolerability of a Single Subcutaneous Injection in Low-Body-Weight Subjects; and Pharmacokinetics at Different Subcutaneous Injection Sites at the Same Dose
Psoriasis, Ankylosing Spondylitis
RecruitingObservational study
Pain Phenotyping of Rheumatic Diseases - An Observational Study
Rheumatic Diseases, Lupus Erythematosus, Systemic
RecruitingObservational study
Identification of Serum Level of Glutathione Peroxidase 4
Spondyloarthropathy
Not yet recruitingPhase 1
A Study of GKL-006Allo Injection in Patients With Ankylosing Spondylitis
Ankylosing Spondylitis
Active, not recruitingObservational study
Neuropathic Spinal Pain in Ankylosing Spondylitis
Ankylosing Spondylitis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Bristol-Myers Squibb, MD study director
Bristol-Myers Squibb
63 sites in 8 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing CC-99677 in people with Spondylitis, Ankylosing, run by Celgene at 63 sites in 8 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: stopped early, as of the sponsor's last update on 1 May 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 63 sites in United States, Poland, Czechia, Turkey (Türkiye), Spain and 3 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 1 May 2024). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Percentage of Participants Who Achieve ASAS 20 at Week 12 (time frame: Week 12). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT04947579, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 May 2024.